A detailed history of Montag A & Associates Inc transactions in Biogen Inc. stock. As of the latest transaction made, Montag A & Associates Inc holds 209 shares of BIIB stock, worth $36,322. This represents 0.0% of its overall portfolio holdings.

Number of Shares
209
Previous 209 -0.0%
Holding current value
$36,322
Previous $45,000 6.67%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

SELL
$253.3 - $285.89 $4,052 - $4,574
-16 Reduced 7.11%
209 $53,000
Q4 2022

Feb 02, 2023

BUY
$252.44 - $306.72 $4,039 - $4,907
16 Added 7.66%
225 $62,000
Q4 2020

Feb 12, 2021

BUY
$236.26 - $355.63 $49,378 - $74,326
209 New
209 $51,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Montag A & Associates Inc Portfolio

Follow Montag A & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Montag A & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Montag A & Associates Inc with notifications on news.